Biopharmaceutical research based on research associated with sirtuin enzymes, with eventual application in diseases associated with aging, such as Type 2 Diabetes. In humans. IPO in 2006, acquired by GSK in 2007. CHP II was founding investor.

Verastem is  focusing on a portfolio of small molecule drugs inhibiting critical signaling pathways in cancer, including the phosphoinositide 3-kinase (PI3K) and focal adhesion kinase (FAK) pathways. These signaling pathways are abnormal in cancer and promote tumor survival. Preclinical research has shown these pathways also contribute to the protective nature of the tumor microenvironment, thereby limiting the effectiveness of existing cancer treatments.

Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. CHP II was founding investor, IPO in 2004.

Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Drug discovery based on glycomics, (the study of complex sugars) Groundbreaking application in the area of developing generic biologics. CHP II was founding investor, June 2004 IPO. Co-Investors: Polaris, Atlas, MVM, Mithra.

Novel drug development platform targeting central nervous system diseases. Platform has generated dozens of drug leads with clinical trials underway in Tourette’s Syndrome, MS and Agitation in Alzheimer’s Patients.  Cardinal Partners is  founding investor.  May 2019 – Acquired by Denmark’s H. Lundbeck A/S.

Vividion is a next generation biotechnology company focused on expanding the therapeutic potential of small molecules. Drug development technology platform for a broad array of protein targets that have heretofore been deemed ‘undruggable’. CHP III is founding investor. August 2021 – acquired by Bayer AG for $2 billion.

aTyr Pharma is a public biotherapeutics company that researches and develops Physiocrine-based therapeutics for treatment of rare diseases with an immune component.. CHP III was initial investor, incubated at Cardinal.

Alkermes plc is a biopharmaceutical company that focuses on central nervous system diseases. The company is the result of a merger in September 2011 between Alkermes, Inc., and Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc